Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
Interested parties may also access a live webcast of the presentation byvisiting the "Events Calendar" page under the "Investors/Press" tab on Kosan'swebsite at http://www.kosan.com. A recorded replay of the presentations willbe available for two weeks.
Kosan Biosciences is a biotechnology company advancing two new classes ofanticancer agents through clinical development -- Hsp90 (heat shock protein90) inhibitors and epothilones. Hsp90 inhibitors have a novel mechanism ofaction targeting multiple pathways involved in cancer cell growth andsurvival. Tanespimycin (KOS-953) is being tested in combination withbortezomib (Velcade(R)) in patients with multiple myeloma in a clinicalprogram called TIME. Tanespimycin is also being studied in HER2-positivemetastatic breast cancer in combination with trastuzumab (Herceptin(R)).Epothilones inhibit cell division with a mechanism of action similar totaxanes, one of the most successful classes of anti-tumor agents. KOS-1584 isin Phase 1 clinical trials in patients with solid tumors. Kosan's motilinagonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial ingastroesophageal reflux disease (GERD).
For additional information on Kosan Biosciences, please visit thecompany's website at http://www.kosan.com.
Velcade(R) (bortezomib) is a registered trademark of MillenniumPharmaceuticals, Inc.
Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.
SOURCE Kosan Biosciences Incorporated
You May Also Like